Regenxbio Inc (RGNX NASDAQ) stock market data APIs
$8.2146
-0.18(-2.2%)
as of July 1, 2025
Try our APIs with
free plan!
Regenxbio Inc Financial Data Overview
Price chart is built with
Anychart
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Prev. Close
8.2146
Open
8.0373
High
8.5072
Low
7.9798
52 wk Range
5.035-15.36
Market Cap
414 M
Shares Outstanding
50 389 K
Revenue
157 M
EPS
0.12
Beta
1.089
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Regenxbio Inc data using free add-ons & libraries
Get Regenxbio Inc Fundamental Data
Regenxbio Inc Fundamental data includes:
- Net Revenue: 157 M
- EBITDA: -141 366 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: 0.4856
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Regenxbio Inc News
New
Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street.
Five years ago, scientists and investors were excited about gene therapy offering one-and-done cures for deadly diseases. Today, much of the enthusiasm has dried up. Continue Reading View Comments
Gene Therapy Has Lost Support on Wall Street. There’s Still Hope for Big Cures.
Five years ago, scientists and investors were excited about gene therapy offering one-and-done cures for deadly diseases. Today, much of the enthusiasm has dried up. Continue Reading Kommentare anzeigen
Solid Biosciences' SWOT analysis: gene therapy stock shows promise amid DMD competition
Solid Biosciences Inc. (NASDAQ:SLDB), a biotechnology company with a market capitalization of $350 million focused on developing gene therapies for rare diseases, has been making significant strides ...
REGENXBIO registers 268K shares for resale
* REGENXBIO (NASDAQ:RGNX [https://seekingalpha.com/symbol/RGNX]) is registering up to 268,096 shares of common stock for resale by a selling stockholder. * Shares are issuable upon exercise of a w...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
